Interview: Judith Greciet – CEO, Onxeo, France
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Address: 101 rue de Tolbiac 75654 Paris Cedex 13 ,France
Tel: +33 (0)1 44 23 60 98
Created in 1964, the National Institute of Health and Medical Research is a public scientific and technological, under the joint supervision of the Ministry of Health and Ministry of Research.
Inserm is the only public research body entirely dedicated to French human health. In 2008 Inserm was givin the responsibility for coordinating strategic, scientific and operational biomedical research. This central role of coordinator is a natural fit due to the scientific quality of our teams, as well as our ability to deliver translational research from bench to bedside.
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Patrick Choay discusses his first foray into the pharmaceutical business world, talks about the highlights of his long and interesting career, his balanced partnership strategy for the Choay Group and…
Marc-Antoine Lucchini, the president-general manager of Sanofi France, talks about their unprecedented number of new molecules and innovations soon to be launched. He also explains the need to focus on the…
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
The CEO of Medicen Paris Region, the biopharma cluster for the Paris region, discusses her vision to develop a world-class cluster and act as a catalyst for innovation; her international…
Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third…
Mr Truelle, the CEO of CDM Lavoisier, a company specialized in the pharmaceutical manufacturing of injectable solutions, reveals that one third of the French population could receive one of the…
Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape…
Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented…
The President of Pfizer France reveals how the biggest challenge the French pharma industry faces is to gain credit for its contribution to improve people´s quality of life; why France…
The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with…
Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic…
See our Cookie Privacy Policy Here
